	US 11,672,831 B2
	Use of adipose tissue-derived stromal stem cells in treating fistula
María Gema Fernández Miguel, Madrid (ES); Manuel Ángel González De La Peña, Madrid (ES); Rosa Ana García Castro, Madrid (ES); Mariano García Arranz, Madrid (ES); and Damián García Olmo, Madrid (ES)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP); and Universidad Autónoma de Madrid, Madrid (ES)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP); and Universidad Autónoma de Madrid, Madrid (ES)
Filed on Mar. 20, 2017, as Appl. No. 15/464,149.
Application 15/464,149 is a continuation of application No. 14/538,681, filed on Nov. 11, 2014, granted, now 10,758,575, issued on Aug. 12, 2020.
Application 14/538,681 is a continuation of application No. 11/993,859, granted, now 8,999,709, issued on Apr. 7, 2015, previously published as PCT/EP2006/004605, filed on May 16, 2006.
Application 11/993,859 is a continuation of application No. 11/167,061, filed on Jun. 24, 2005, abandoned.
Prior Publication US 2017/0189451 A1, Jul. 6, 2017
Int. Cl. C12N 5/0775 (2010.01); A61K 35/35 (2015.01); A61L 24/10 (2006.01); A61L 27/36 (2006.01); A61L 27/38 (2006.01); A61B 17/16 (2006.01); A61K 45/06 (2006.01); A61L 24/00 (2006.01); A61B 17/32 (2006.01); A61K 35/12 (2015.01)

CPC A61K 35/35 (2013.01) [A61B 17/1659 (2013.01); A61B 17/32 (2013.01); A61K 45/06 (2013.01); A61L 24/0015 (2013.01); A61L 24/106 (2013.01); A61L 27/3604 (2013.01); A61L 27/3834 (2013.01); A61L 27/3839 (2013.01); A61L 27/3869 (2013.01); A61L 27/3895 (2013.01); C12N 5/0667 (2013.01); A61B 2017/320008 (2013.01); A61K 35/12 (2013.01); A61L 2300/64 (2013.01); C12N 2509/00 (2013.01); C12N 2510/00 (2013.01); C12N 2533/56 (2013.01)]

12 Claims

1. A method for treatment of fistulas comprising administering to a subject at least two pharmaceutically acceptable doses of adipose tissue-derived stromal stem cells in admixture with a pharmaceutically acceptable carrier using a kit, wherein the adipose tissue-derived stromal stem cells are at a concentration of at least 5×10⁶cells/mL and each dose comprises at least 20×10⁶cells, wherein the pharmaceutically acceptable carrier comprises an effective amount of Dulbecco's Modified Eagle's Medium (DMEM) and human serum albumin (HSA) to stabilize the adipose tissue-derived stromal stem cells under storage conditions, wherein the adipose tissue-derived stromal stem cells are allogeneic with respect to the subject, and the adipose tissue-derived stromal stem cells were not matched for MHC compatibility with the subject and the subject does not receive an immunosuppressive agent to prevent rejection of the adipose tissue-derived stromal stem cells.